Nektar Therapeutics (LTS:0UNL)
$ 1.3895 0.0495 (3.69%) Market Cap: 257.71 Mil Enterprise Value: 98.58 Mil PE Ratio: 0 PB Ratio: 3.09 GF Score: 54/100

Nektar Therapeutics at Cowen HealthCare Conference Transcript

Mar 03, 2020 / 02:20PM GMT
Release Date Price: $23.73
Chris Shibutani
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

(technical difficulty)

Chris Shibutani. I'm a member of the Cowen biotech team. We are thrilled to once again have Nektar Therapeutics join us at our 40th Annual Cowen Healthcare Conference.

Nektar has always been about some really potent core capabilities, technology and capabilities that have really been applied in some of the toughest challenges. Not everything always works. But I think, particularly from the standpoint of being able to establish a commercial business, these guys PEGylate stuff like nobody's business. I think they have tried to take on some of the most important challenges, and there have been sometimes bumps in the road, but now there's a deep commitment and a deepening layer of science to everything that they do. And with that, they're targeting areas in oncology, autoimmune disease. And these are never 4- to 7-quarter journeys. They're 4- to 7-year journeys. And the good news is we're quite a few years into those journeys. So I think this is a particularly opportune time

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot